{
    "clinical_study": {
        "@rank": "3012", 
        "arm_group": {
            "arm_group_label": "Chronic hepatitis B patients", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This cross-sectional multicenter study will evaluate the IL28B polymorphism in patients with\n      HBeAg-negative chronic hepatitis B treated with Pegasys (peginterferon alfa-2a) in the\n      predecessor ML18253 study. The study consists of a single visit where eligible patients will\n      undergo a blood test for IL28B genotyping, with a phone follow-up 7 days after the visit."
        }, 
        "brief_title": "A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML18253", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Hepatitis B, Chronic", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Hepatitis, Chronic", 
                "Hepatitis B, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Chronic hepatitis B\n\n          -  Previous participation in study ML18253\n\n          -  Administration of at least one dose of the study drug during ML18253 study\n\n        Exclusion Criteria:\n\n          -  Patients not satisfying the above inclusion criteria will not be enrolled in the\n             study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "88", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01697501", 
            "org_study_id": "ML28470", 
            "secondary_id": "2012-002777-56"
        }, 
        "intervention": {
            "arm_group_label": "Chronic hepatitis B patients", 
            "description": "Blood sampling for IL28B genotyping", 
            "intervention_name": "Interleukin 28B testing", 
            "intervention_type": "Other"
        }, 
        "intervention_browse": {
            "mesh_term": "Peginterferon alfa-2a"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Caserta", 
                        "country": "Italy", 
                        "state": "Campania", 
                        "zip": "81100"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Napoli", 
                        "country": "Italy", 
                        "state": "Campania", 
                        "zip": "80131"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bologna", 
                        "country": "Italy", 
                        "state": "Emilia-Romagna", 
                        "zip": "40138"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Parma", 
                        "country": "Italy", 
                        "state": "Emilia-Romagna", 
                        "zip": "43100"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "state": "Lombardia", 
                        "zip": "20122"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bari", 
                        "country": "Italy", 
                        "state": "Puglia", 
                        "zip": "70124"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Castellana Grotte", 
                        "country": "Italy", 
                        "state": "Puglia", 
                        "zip": "70013"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cagliari", 
                        "country": "Italy", 
                        "state": "Sardegna", 
                        "zip": "09042"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palermo", 
                        "country": "Italy", 
                        "state": "Sicilia", 
                        "zip": "90127"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pisa", 
                        "country": "Italy", 
                        "state": "Toscana", 
                        "zip": "56124"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Padova", 
                        "country": "Italy", 
                        "state": "Veneto", 
                        "zip": "35128"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "1", 
        "official_title": "Cross-sectional Multicenter Study Evaluating the IL28B Polymorphism in Patients With HBeAg-negative Chronic Hepatitis B Treated With Pegylated Interferon Alfa-2a in the Course of Peg.Be.Liver Study", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Italy: Agenzia Italiana del Farmaco (AIFA)"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Percentage of patients with sustained virological response (SVR) observed in ML18253 according to IL28B genotypes. SVR is defined as HBV DNA </= 2000 UI/ml at the end of the treatment-free follow-up", 
            "safety_issue": "No", 
            "time_frame": "approximately 24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01697501"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of patients with HBsAg clearance (defined as HBsAg <0.05 UI/ml) according to IL28B genotypes at end of treatment/end of follow-up in ML18253", 
                "safety_issue": "No", 
                "time_frame": "approximately 24 weeks"
            }, 
            {
                "measure": "Percentage of patients with HBsAg </= 10 IU/ml at end of treatment/end of follow-up according to IL28B genotypes in ML18253", 
                "safety_issue": "No", 
                "time_frame": "approximately 24 weeks"
            }, 
            {
                "measure": "HBsAg kinetic according to IL28B genotypes during treatment/follow-up in ML18253", 
                "safety_issue": "No", 
                "time_frame": "approximately 24 weeks"
            }, 
            {
                "measure": "Percentage of patients with virologic response at the end of treatment (HBV DNA </= 200 UI/ml) observed in ML18253 according to IL28B genotype.", 
                "safety_issue": "No", 
                "time_frame": "approximately 24 months"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}